DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 189 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.96 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,994,350 | -25.3% | 707,103 | -17.3% | 0.05% | -23.2% |
| Q2 2023 | $12,042,272 | -11.2% | 855,275 | -2.6% | 0.07% | -16.9% |
| Q1 2023 | $13,567,217 | -32.2% | 878,137 | -28.0% | 0.08% | -38.5% |
| Q4 2022 | $19,997,112 | -17.6% | 1,220,080 | -7.0% | 0.14% | -29.7% |
| Q3 2022 | $24,264,000 | +53.9% | 1,311,556 | +9.4% | 0.19% | +57.4% |
| Q2 2022 | $15,767,000 | +577.9% | 1,199,009 | +377.8% | 0.12% | +662.5% |
| Q1 2022 | $2,326,000 | -5.5% | 250,940 | -0.4% | 0.02% | 0.0% |
| Q4 2021 | $2,462,000 | +251.2% | 252,017 | +1121.3% | 0.02% | +220.0% |
| Q3 2021 | $701,000 | -75.0% | 20,635 | -73.1% | 0.01% | -73.7% |
| Q2 2021 | $2,803,000 | -44.2% | 76,572 | -31.6% | 0.02% | -51.3% |
| Q1 2021 | $5,021,000 | +125.4% | 111,983 | +186.9% | 0.04% | +95.0% |
| Q4 2020 | $2,228,000 | – | 39,036 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 4,104,140 | $93,041,000 | 43.52% |
| SV Health Investors, LLC | 1,716,303 | $38,909,000 | 20.55% |
| PURA VIDA INVESTMENTS, LLC | 68,154 | $1,545,000 | 0.65% |
| Redmile Group, LLC | 683,880 | $14,658,000 | 0.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 77,000 | $1,746,000 | 0.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 224,154 | $5,008,000 | 0.59% |
| EMERALD ADVISERS, LLC | 482,626 | $10,941,000 | 0.42% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 416,342 | $9,438,000 | 0.38% |
| Orbimed Advisors | 1,176,070 | $26,662,000 | 0.34% |
| VIKING GLOBAL INVESTORS LP | 2,394,625 | $54,286,000 | 0.33% |